Company intelligence / Profile preview
Marea Therapeutics
San Francisco, California, United Statesmareatx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Marea’s lead program, MAR001, is in Phase 2 clinical development targeting remnant cholesterol in adults with metabolic dysfunction at high cardiovascular risk. The company leverages human genetics and adipose biology to address unaddressed drivers of cardiometabolic disease. Additional programs are in discovery or preclinical stages.
- Therapeutic areas
- EndocrinologyCardiovascularMetabolic Disorders
- Modalities
- Small moleculesMonoclonal antibodiesBiological products
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Marea Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Marea Therapeutics.